Vertex Pharmaceuticals Incorporated (0QZU.L)
| Previous close | 392.91 |
| Open | 394.19 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 391.63 - 394.83 |
| 52-week range | 290.87 - 446.29 |
| Volume | |
| Avg. volume | 2,907 |
| Market cap | 1.012B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 0.42 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
- Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Director
- Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
BOSTON, April 09, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2024 Earnings Call."
